| Literature DB >> 31560382 |
Manja Koch1, Annette L Fitzpatrick2,3,4, Stephen R Rapp5, Richard L Nahin6, Jeff D Williamson7, Oscar L Lopez8, Steven T DeKosky9, Lewis H Kuller10, Rachel H Mackey8, Kenneth J Mukamal1,11, Majken K Jensen1,12, Kaycee M Sink13.
Abstract
Importance: Substantial heterogeneity and uncertainty exist in the observed associations between alcohol consumption and dementia. Objective: To assess the association between alcohol consumption and dementia and the roles of mild cognitive impairment (MCI) and apolipoprotein E ε4 (APOE E4) genotype in modifying this association. Design, Setting, and Participants: This cohort study used data from the Ginkgo Evaluation of Memory Study, conducted from 2000 to 2008 among US community-dwelling participants. This study analyzed 3021 participants aged 72 years and older who were free of dementia. Data analysis was performed from 2017 to 2018. Exposures: Self-reported alcohol consumption, drinking frequency, and quantity. Main Outcomes and Measures: Using multivariable proportional hazards regression and linear mixed models, the risk of dementia and the rate of change over time in the Modified Mini-Mental State Examination were estimated.Entities:
Year: 2019 PMID: 31560382 PMCID: PMC6777245 DOI: 10.1001/jamanetworkopen.2019.10319
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Characteristics of 3021 Participants of the Ginkgo Evaluation of Memory Study According to Usual Alcohol Consumption
| Characteristic | Participants, No. (%) | ||||
|---|---|---|---|---|---|
| Nondrinkers (n = 1286) | 0.1-0.9 Drinks/wk (n = 466) | 1.0-7.0 Drinks/wk (n = 689) | 7.1-14.0 Drinks/wk (n = 286) | >14.0 Drinks/wk (n = 294) | |
| Weekly drinks, median (IQR), No. | 0 (0-0) | 0.2 (0.06-0.46) | 2.0 (1.2-4.0) | 8.2 (7.5-14.0) | 16.0 (14.7-21.5) |
| Wine | 0 (0-0) | 0.2 (0.02-0.23) | 1.0 (0.2-1.0) | 7.0 (0.2-7.0) | 2.0 (0.2-14.0) |
| Beer | 0 (0-0) | 0 (0-0.02) | 0 (0-1.0) | 0.2 (0-1.0) | 0.2 (0-2.0) |
| Liquor | 0 (0-0) | 0 (0-0.08) | 0.2 (0-1.0) | 0.7 (0-7.0) | 14.0 (0.5-14.0) |
| Age, median (IQR), y | 78 (76-81) | 78 (76-80) | 78 (76-80) | 78 (76-81) | 77 (76-80) |
| Female | 716 (56) | 239 (51) | 288 (42) | 92 (32) | 60 (20) |
| White | 1199 (93) | 446 (96) | 666 (97) | 281 (98) | 292 (99) |
| Education, median (IQR), y | 13 (12-16) | 14 (12-17) | 15 (12-17) | 16 (13-17) | 16 (13-17) |
| Engagement in social activity | |||||
| Never or <1 time/mo | 85 (7) | 26 (6) | 28 (4) | 15 (5) | 13 (4) |
| 1-3 times/mo | 430 (33) | 160 (34) | 235 (34) | 105 (37) | 111 (38) |
| ≥1 times/wk | 771 (60) | 280 (60) | 426 (62) | 166 (58) | 170 (58) |
| Body mass index | |||||
| Underweight | 36 (3) | 6 (1) | 14 (2) | 2 (1) | 5 (2) |
| Normal weight | 369 (29) | 142 (31) | 219 (32) | 104 (36) | 77 (26) |
| Overweight | 566 (44) | 185 (40) | 340 (49) | 139 (49) | 158 (54) |
| Obese | 308 (24) | 132 (28) | 116 (17) | 40 (14) | 51 (18) |
| Smoking status | |||||
| Never | 669 (53) | 200 (44) | 205 (30) | 81 (29) | 53 (18) |
| Former | 551 (44) | 231 (51) | 438 (65) | 191 (68) | 214 (74) |
| Current | 42 (3) | 23 (5) | 36 (5) | 10 (4) | 24 (8) |
| History | |||||
| Cardiovascular disease | 425 (33) | 154 (33) | 220 (32) | 98 (34) | 94 (32) |
| Diabetes | 152 (12) | 43 (9) | 48 (7) | 17 (6) | 16 (5) |
| Diastolic blood pressure, median (IQR), mm Hg | 69 (61-75) | 69 (62-74) | 69 (61-76) | 69 (62-75) | 70 (62-77) |
| Lipid-lowering medication use | 375 (29) | 139 (30) | 180 (26) | 72 (25) | 76 (26) |
| Center for Epidemiologic Studies Depression Scale score, median (IQR) | 3 (1-6) | 3 (1-5) | 3 (1-5) | 3 (1-5) | 3 (1-5) |
| Death during follow-up | 167 (13) | 51 (11) | 89 (13) | 30 (10) | 40 (14) |
| Mild cognitive impairment | 260 (20) | 60 (13) | 89 (13) | 36 (13) | 28 (10) |
| Modified Mini-Mental State Examination score, median (IQR) | 93 (89-96) | 95 (92-98) | 95 (91-97) | 95 (91-98) | 95 (92-97) |
| Alzheimer’s Disease Assessment Scale cognitive score, median (IQR) | 6 (5-8) | 6 (4-8) | 6 (5-8) | 6 (5-8) | 6 (5-8) |
| 243 (24) | 97 (26) | 141 (26) | 47 (21) | 43 (18) | |
| Dementia | 254 (20) | 74 (16) | 103 (15) | 38 (13) | 43 (15) |
| Alzheimer | 169 (13) | 46 (10) | 76 (11) | 29 (10) | 28 (10) |
| Vascular | 7 (1) | 7 (2) | 6 (1) | 1 (<1) | 2 (1) |
| Mixed | 67 (5) | 17 (4) | 18 (3) | 6 (2) | 11 (4) |
| Other | 11 (1) | 4 (1) | 3 (<1) | 2 (1) | 2 (1) |
Abbreviation: IQR, interquartile range.
Sample size was 3009. Body mass index is calculated as weight in kilograms divided by height in meters squared (underweight, <20; normal, 20-24.9; overweight, 25-29.9; obese, ≥30).
Sample size was 2968.
Sample size was 2416.
Figure. Risk of Dementia in Participants With and Without Mild Cognitive Impairment (MCI) at Baseline by Self-reported Weekly Number of Drinks
Plots show log hazard ratios (solid lines) and 95% confidence intervals (dashed lines) for risk of dementia by self-reported weekly number of drinks among 2548 participants without MCI at baseline (A) and 473 participants with MCI at baseline (B). Log hazard ratios were obtained from a generalized additive proportional hazards model with 3 df adjusted for age, sex, race/ethnicity, clinic site, educational level, social activity, smoking status, body mass index, lipid-lowering medication use, history of cardiovascular disease, diabetes, Center for Epidemiologic Studies Depression Scale score, treatment group assignment, and APOE genotype.
Adjusted HRs of Dementia According to Usual Alcohol Consumption Among 3021 Participants of the Ginkgo Evaluation of Memory Study
| Characteristic | Weekly No. of Drinks | ||||||
|---|---|---|---|---|---|---|---|
| Nondrinkers | 0.1-0.9 | 1.0-7.0 | 7.1-14.0 | >14.0 | Linear | Quadratic | |
| No cognitive impairment at baseline (n = 2548) | |||||||
| Participants, No. | |||||||
| With dementia | 151 | 50 | 68 | 22 | 26 | ||
| Without dementia | 875 | 356 | 532 | 228 | 240 | ||
| HR (95% CI) | |||||||
| Basic model | 1.14 (0.82-1.57) | 1 [Reference] | 0.94 (0.65-1.35) | 0.67 (0.40-1.11) | 0.87 (0.54-1.42) | .10 | .17 |
| Full model | 1.17 (0.84-1.62) | 1 [Reference] | 0.88 (0.61-1.28) | 0.63 (0.38-1.06) | 0.91 (0.56-1.48) | .10 | .07 |
| Mild cognitive impairment at baseline (n = 473) | |||||||
| Participants, No. | |||||||
| With dementia | 103 | 24 | 35 | 16 | 17 | ||
| Without dementia | 157 | 36 | 54 | 20 | 11 | ||
| HR (95% CI) | |||||||
| Basic model | 1.02 (0.65-1.60) | 1 [Reference] | 0.97 (0.57-1.66) | 1.13 (0.58-2.17) | 1.63 (0.86-3.11) | .11 | .81 |
| Full model | 0.98 (0.62-1.56) | 1 [Reference] | 0.90 (0.52-1.57) | 0.93 (0.47-1.84) | 1.72 (0.87-3.40) | .13 | .40 |
Abbreviation: HR, hazard ratio.
HRs were obtained from Cox proportional hazard regression models with age as the underlying time axis adjusted for sex, race/ethnicity, and clinic site. Full models were also adjusted for education, social activity, smoking status, body mass index, lipid-lowering medication use, history of cardiovascular disease, diabetes, Center for Epidemiologic Studies Depression Scale score, treatment group assignment, and APOE genotype.
Adjusted HRs of All-Cause Dementia According to Self-reported Frequency of Alcohol Consumption and Quantity of Alcohol Consumed per Drinking Day in a Subset of 2095 Participants Without Cognitive Impairment at Baseline Who Consumed Preferentially 1 Beverage Type
| Characteristic | Drinking d/wk | |||||
|---|---|---|---|---|---|---|
| Nondrinkers | <1 | 1-6 | 7 | |||
| 1 Drink/d | ≥2 Drinks/d | 1 Drink/d | ≥2 Drinks/d | |||
| Participants, No. | ||||||
| With dementia | 151 | 36 | 24 | 14 | 23 | 28 |
| Without dementia | 875 | 238 | 191 | 71 | 217 | 227 |
| HR (95% CI) | 1.18 (0.81-1.72) | 1 [Reference] | 0.93 (0.55-1.57) | 1.54 (0.82-2.90) | 0.69 (0.40-1.19) | 1.03 (0.61-1.71) |
Abbreviation: HR, hazard ratio.
HRs were obtained from Cox proportional hazard regression models with age as the underlying time axis adjusted for sex, race/ethnicity, clinic site, education, social activity, smoking status, body mass index, lipid-lowering medication use, history of cardiovascular disease, diabetes, Center for Epidemiologic Studies Depression Scale score, treatment group assignment, and APOE genotype.
Difference in Cognitive Scores at Follow-up According to Self-reported Usual Alcohol Consumption of 3006 Ginkgo Evaluation of Memory Study Participants
| Characteristic | Difference (95% CI) in Cognitive Scores at Follow-up According to Weekly No. of Drinks | |||||
|---|---|---|---|---|---|---|
| Nondrinkers | 0.1-0.9 Drinks/wk | 1.0-7.0 Drinks/wk | 7.1-14.0 Drinks/wk | >14.0 Drinks/wk | ||
| No cognitive impairment at baseline | ||||||
| Modified Mini-Mental State Examination score (n = 2509) | ||||||
| Basic model | −0.47 (−0.88 to −0.05) | 0 | −0.41 (−0.87 to 0.04) | 0.12 (−0.45 to 0.69) | −0.23 (−0.78 to 0.33) | .06 |
| Full model | −0.46 (−0.87 to −0.04) | 0 | −0.41 (−0.86 to 0.05) | 0.14 (−0.43 to 0.71) | −0.22 (−0.77 to 0.34) | .06 |
| Alzheimer’s Disease Assessment Scale cognitive score (n = 2548) | ||||||
| Basic model | 0.15 (−0.08 to 0.37) | 0 | 0.07 (−0.18 to 0.31) | 0.07 (−0.24 to 0.37) | −0.10 (−0.39 to 0.20) | .39 |
| Full model | 0.14 (−0.08 to 0.36) | 0 | 0.06 (−0.18 to 0.30) | 0.06 (−0.24 to 0.37) | −0.10 (−0.40 to 0.19) | .40 |
| Mild cognitive impairment at baseline | ||||||
| Modified Mini-Mental State Examination score (n = 455) | ||||||
| Basic model | −0.87 (−2.29 to 0.55) | 0 | −1.59 (−3.28 to 0.09) | 0.01 (−2.12 to 2.14) | −3.49 (−5.72 to −1.27) | .02 |
| Full model | −0.87 (−2.29 to 0.56) | 0 | −1.58 (−3.28 to 0.11) | −0.01 (−2.15 to 2.13) | −3.51 (−5.75 to −1.27) | .02 |
| Alzheimer’s Disease Assessment Scale cognitive score (n = 473) | ||||||
| Basic model | −0.12 (−0.85 to 0.60) | 0 | 0.06 (−0.80 to 0.92) | −0.16 (−1.24 to 0.92) | 0.47 (−0.68 to 1.63) | .81 |
| Full model | −0.12 (−0.84 to 0.61) | 0 | 0.05 (−0.81 to 0.91) | −0.18 (−1.26 to 0.90) | 0.48 (−0.68 to 1.63) | .82 |
Difference in Modified Mini-Mental State Examination score or Alzheimer’s Disease Assessment Scale cognitive score at follow-up obtained from linear mixed models adjusted for age, sex, race/ethnicity, and clinic site.
Also adjusted for education, social activity, smoking status, body mass index, lipid-lowering medication use, history of cardiovascular disease, diabetes, depression (Center for Epidemiologic Studies Depression Scale score), treatment group assignment, and APOE genotype.